



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Zeyu Wu

✉ wu.zeyu@hotmail.com

[†]These authors have contributed
equally to this work and share
first authorship

RECEIVED 26 October 2024

ACCEPTED 31 October 2024

PUBLISHED 15 November 2024

CITATION

Huang J, Shi H, Song M, Liang J, Zhang Z,
Chen X, Liu Y, Wang S and Wu Z (2024)
Corrigendum: Surgical outcome and
malignant risk factors in patients with thyroid
nodule classified as Bethesda category III.
Front. Endocrinol. 15:1517690.
doi: 10.3389/fendo.2024.1517690

COPYRIGHT

© 2024 Huang, Shi, Song, Liang, Zhang, Chen,
Liu, Wang and Wu. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: Surgical outcome and malignant risk factors in patients with thyroid nodule classified as Bethesda category III

Jianhao Huang^{1,2†}, Hongyan Shi^{1,3†}, Muye Song^{1,4†}, Jinan Liang^{1,3},
Zhiyuan Zhang^{1,3}, Xiaohang Chen^{1,2}, Yongchen Liu¹,
Sanming Wang¹ and Zeyu Wu^{1*}

¹Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of
Medical Sciences, Guangzhou, China, ²Shantou University Medical College, Shantou, China, ³The
Second School of Clinical Medicine, Southern Medical University, Guangzhou, China, ⁴School of
Medicine, South China University of Technology, Guangzhou, China

KEYWORDS

thyroid cancer, autoimmune thyroid antibodies, tumor size, fine needle aspirate
(FNA), microcalcification

A Corrigendum on

**Surgical outcome and malignant risk factors in patients with thyroid
nodule classified as Bethesda category III**

By Huang J, Shi H, Song M, Liang J, Zhang Z, Chen X, Liu Y, Wang S and Wu Z (2021) *Front.
Endocrinol.* 12:686849. doi: 10.3389/fendo.2021.686849

In the published article, there was an error in the Funding statement. The Funding statement for the Guangdong Basic and Applied Basic Research Foundation was displayed as “Natural Science Foundation of Guangdong Province (No. 2020A1515010127)”. The correct statement is “Guangdong Basic and Applied Basic Research Foundation (No. 2020A1515010126)”. The correct Funding statement appears below.

“This work was supported by Guangdong Basic and Applied Basic Research Foundation (No. 2020A1515010126), Scientific Research Staring Foundation for the Returned Overseas from Guangdong Provincial People's Hospital (No. 2017x02) and Guangdong Provincial People's Hospital Scientific Foundation for Distinguished Young Scholars of Guangdong Province (No. KJ012019441).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.